Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.56 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | TOP2A | P11388 | 3/20 | 0.41 |
| ▸ | TOP2B | Q02880 | 3/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2082888 | 1.00 | CYP3A4 (0.65) | CYP3A4KCNH2SCN5AALDH1A1POLB | |
| SCHEMBL2081913 | 0.89 | CYP3A4 (0.81) | CYP3A4KCNH2SCN5AALDH1A1POLB | |
| SCHEMBL2081915 | 0.89 | CYP3A4 (0.81) | CYP3A4KCNH2SCN5AALDH1A1POLB | |
| SCHEMBL2082314 | 0.87 | KCNH2 (0.52) | CYP3A4KCNH2ALDH1A1POLBCHRM2 | |
| SCHEMBL2082315 | 0.87 | KCNH2 (0.52) | CYP3A4KCNH2ALDH1A1POLBCHRM2 | |
| SCHEMBL2082942 | 0.86 | CYP3A4 (0.76) | CYP3A4KCNH2SCN5AALDH1A1POLB | |
| SCHEMBL2082941 | 0.86 | CYP3A4 (0.76) | CYP3A4KCNH2SCN5AALDH1A1POLB | |
| SCHEMBL2083993 | 0.85 | CYP3A4 (0.68) | CYP3A4KCNH2SCN5AALDH1A1POLB | |
| SCHEMBL2083997 | 0.85 | CYP3A4 (0.68) | CYP3A4KCNH2SCN5AALDH1A1POLB | |
| SCHEMBL14410645 | 0.84 | KCNH2 (0.51) | CYP3A4KCNH2ALDH1A1POLBCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902226-B2 | Dehalogeno-compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-03-08 | — | — | US | disclosed |
| EP-1336611-B1 | DEHALOGENO COMPOUNDS | DAIICHI SEIYAKU CO (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-20070123560-A1 | Dehalogeno-compounds | DAIICHI PHARMACEUTICAL CO., LTD. | 2007-05-31 | — | — | US | disclosed |
| US-20040063754-A1 | Dehalogeno compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1336611-A1 | DEHALOGENO COMPOUNDS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063754-A1 | Dehalogeno compounds | DEK, PGLS, RPS27L | CYP3A4 198/4885KCNH2 1597/4885SCN5A 1495/4885 |
| US-20070123560-A1 | Dehalogeno-compounds | DEK, RPS27L, POLL | CYP3A4 277/4885KCNH2 1059/4885SCN5A 1594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.